Ochre Bio

Oxford, United Kingdom Founded: 2019 • Age: 7 yrs
Genomic medicines for liver diseases are developed using gene therapies.

About Ochre Bio

Ochre Bio is a company based in Oxford (United Kingdom) founded in 2019.. Ochre Bio has raised $39.73 million across 3 funding rounds from investors including Khosla Ventures, Lifelink Systems and Backed. The company has 11 employees as of January 31, 2022. Ochre Bio offers products and services including RNA Therapies, Genomic Platform, and Validation Platform. Ochre Bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.

  • Headquarter Oxford, United Kingdom
  • Employees 11 as on 31 Jan, 2022
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Ochre Bio Ltd
  • Date of Incorporation 04 Nov, 2019
  • Jurisdiction OXFORD, ENGLAND
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
    $-13.63 M (USD)
    0
    as on Dec 31, 2022
  • EBITDA
  • Total Equity Funding
    $39.73 M (USD)

    in 3 rounds

  • Latest Funding Round
    $30 M (USD), Series A

    Oct 10, 2022

  • Investors
  • Employee Count
    11

    as on Jan 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Ochre Bio

Ochre Bio offers a comprehensive portfolio of products and services, including RNA Therapies, Genomic Platform, and Validation Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Develops treatments for liver diseases using RNA platforms

Analyzes human liver data for therapy discovery

Tests therapies in human systems for disease validation

People of Ochre Bio
Headcount 10-50
Employee Profiles 31
Board Members and Advisors 10
Employee Profiles
People
Quin Wills
Co-Founder & CSO
People
Paul Foster
Acting CFO
People
Stephanie Barnett-Dean
Senior Manager, Group Financial Controller
People
Massoud Malang
Head Of IT And Cybersecurity

Unlock access to complete

Funding Insights of Ochre Bio

Ochre Bio has successfully raised a total of $39.73M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $30 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series A — $30.0M
  • First Round

    (18 Mar 2020)

  • Investors Count 14
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2022 Amount Series A - Ochre Bio Valuation Khosla Ventures
Jun, 2021 Amount Seed - Ochre Bio Valuation Khosla Ventures
Mar, 2020 Amount Seed - Ochre Bio Valuation Y Combinator
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Ochre Bio

Ochre Bio has secured backing from 14 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Khosla Ventures, Lifelink Systems and Backed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Early-stage startups are funded by this venture capital firm.
Founded Year Domain Location
Venture capital firm providing seed funding and community support to founders
Founded Year Domain Location
Early-stage venture capital investments in healthcare and biotech are made.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Ochre Bio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Ochre Bio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Ochre Bio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Ochre Bio

Ochre Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for genetic diseases are developed through targeted interventions.
domain founded_year HQ Location
Gene therapies for rare diseases including retinal dystrophies are developed.
domain founded_year HQ Location
RNA interference-based therapeutics are developed for multiple disorders.
domain founded_year HQ Location
A biopharmaceutical company accelerating innovative mental health treatments.
domain founded_year HQ Location
An AI-enabled platform is developed for infectious disease treatment.
domain founded_year HQ Location
Therapeutics for rare and ultra-rare metabolic diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Ochre Bio

Frequently Asked Questions about Ochre Bio

When was Ochre Bio founded?

Ochre Bio was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Ochre Bio located?

Ochre Bio is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.

Who is the current CEO of Ochre Bio?

Jack Omeara is the current CEO of Ochre Bio.

Is Ochre Bio a funded company?

Ochre Bio is a funded company, having raised a total of $39.73M across 3 funding rounds to date. The company's 1st funding round was a Seed of $125K, raised on Mar 18, 2020.

How many employees does Ochre Bio have?

As of Jan 31, 2022, the latest employee count at Ochre Bio is 11.

What does Ochre Bio do?

Founded in 2019 in Oxford, United Kingdom, Ochre Bio operates in the biotechnology sector. Genomic medicines are developed to address liver diseases through gene therapies that identify and inactivate over-active genes. These therapies support liver transplantation and help prevent fatty liver conditions. A genetic atlas of the human liver has been created via sequencing technologies, with algorithms employed to analyze resulting data sets for deeper disease insights.

Who are the top competitors of Ochre Bio?

Ochre Bio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.

What products or services does Ochre Bio offer?

Ochre Bio offers RNA Therapies, Genomic Platform, and Validation Platform.

Who are Ochre Bio's investors?

Ochre Bio has 14 investors. Key investors include Khosla Ventures, Lifelink Systems, Backed, Apollo Health Ventures, and Hoxton Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available